Mechanistic and preclinical evaluation of SIRT3 as a therapeutic target in melanoma.

This decrease was also seen in the final tumor weight after 4′-BR treatment, with a significant decrease seen in the Mel-PDX-01, and results close to significance in the TM01137 (not reached due to one large outlier; p value = 0.1150) ( Figure 6(C , E) ).

also in 2,130 other papers

Although the reduction in tumor volume did not reach statistical significance, both PDX models exhibited a trend toward decreased tumor burden following siSIRT3 treatment compared with the non-targeting control (siNTC), with the strongest effect observed in the Mel-PDX-01 model ( Figure 4(B , D) ).

also in 111,027 other papers